NCT03378102View on ClinicalTrials.gov

Antigen Specific Adoptive T Cell Therapy for Adenovirus Infection After Hematopoietic Stem Cell Transplantation

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2028

Conditions
Allogeneic Hematopoietic Stem Cell Transplantation
Interventions
BIOLOGICAL

IFN-gamma-secreting HAdV antigen specific T cells

Antigen selected cells will be obtained using the CliniMACS(R) Prodigy System from a compatible donor. Isolated cells will be infused into the donor to treat human adenoviral infection after transplant

Trial Locations (1)

44106

RECRUITING

University Hospitals, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland

All Listed Sponsors
lead

Mari Dallas

OTHER